Skip to main content
Signal8

NRX Pharmaceuticals, Inc. (NRXP)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NASDAQ:NRXPHealthcare
AH-0.34%$2.37
Close$2.38+0.00%
Mkt Cap$103.04M
Float41.51M
O/S43.3M
VOL876K sh
$ Vol$2.08M
RVOL0.51×
Inst Own28.1%
SI24.0%
Dilution
NRx Pharmaceuticals, Inc. logoNASDAQ:NRXPAH$2.37-0.34%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 20262.382.442.262.38875,910
Nov 6, 20262.302.402.262.38604,422
Nov 5, 20262.462.482.242.27832,744
Nov 4, 20262.302.512.302.491,130,891
Nov 3, 20262.172.342.112.241,799,901
Nov 2, 20262.322.442.142.172,510,313
Oct 30, 20262.832.842.112.2715,641,669
Oct 29, 20262.702.772.622.661,760,886
Oct 28, 20262.732.742.642.69834,661
Oct 27, 20262.592.712.532.69749,685
Oct 26, 20262.482.592.462.55594,734
Oct 23, 20262.362.502.242.49840,297
Oct 22, 20262.572.612.362.401,051,688
Oct 21, 20262.652.702.612.63526,553
Oct 20, 20262.632.772.542.621,348,553
Oct 19, 20262.812.812.622.631,093,428
Oct 16, 20262.702.762.572.601,226,911
Oct 15, 20262.532.772.482.711,177,680
Oct 14, 20262.642.712.562.59696,336
Oct 13, 20262.852.852.672.70553,870
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
5
HOLD
0
SELL
0
TOTAL5
Insider Trades
InsiderTypeShares
Javitt Jonathan C profile photoJavitt Jonathan CGrant/Award150.0K
ABRAMS MICHAEL S profile photoABRAMS MICHAEL SGrant/Award75.0K
Casper Joseph Michael profile photoCasper Joseph MichaelGrant/Award100.0K
Javitt Jonathan C profile photoJavitt Jonathan CGrant/Award125.0K
Flynn Patrick John profile photoFlynn Patrick JohnGrant/Award50.0K
McBride Dennis profile photoMcBride DennisGrant/Award25.0K
Shareholders
28.1%
Institutional
(45)
0.2%
Insiderⓘ
(1)
4.0%
5%+ Owners
(1)
67.7%
Unattributed (incl. retail)ⓘ
Institutional28.1%
Insider0.2%
5%+ Beneficial4.0%
Unattributed (incl. retail)67.7%
Sources: 13F, Form 4, 13D/13GO/S: 43.3M · as of 14 Aug 2026 · SEC filings
Insiders & Institutional Holders

Insiders

Top institutional holders

About

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases.

Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19.

Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Key Metrics
Market Cap$103.04M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership28.13%

based on 43.30M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateDec 4, 2017
Shares Outstanding43.30M
Authorized Shares
Float41.51M
52-Week Range
$1.62$5.05
$2.38(22nd percentile)
Volume
Average Daily Volume1.71M
875.91K today vs 1.71M avg(-49%)

30d Avg

1.71M

60d Avg

1.20M

90d Avg

1.04M

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...